[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545891":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":34,"responsibleParty":52,"collaborators":30,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":30,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":36,"whyStopped":30,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Combined treatment group","EXPERIMENTAL","After screening and signing informed consent, patients who met the admission requirements received 4 cycles of neoadjuvant therapy with irinotecan liposome II combined with 5-FU\u002FLV and oxaliplatin before surgery.\n\nSurgery was performed within 2 to 4 weeks after the end of neoadjuvant therapy. 4 to 6 weeks after surgery, 4 cycles of postoperative adjuvant therapy with irinotecan liposome II combined with 5-FU\u002FLV and oxaliplatin was performed according to the investigator's judgment (once every 2 weeks, a 2-week cycle).",[13],"Drug: irinotecan liposome II combined with 5-FU\u002FLV and oxaliplatin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","irinotecan liposome II combined with 5-FU\u002FLV and oxaliplatin","irinotecan liposome II: 60mg\u002Fm2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg\u002Fm2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg\u002Fm2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg\u002Fm2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.\n\nIrinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs.",[9],[21],"surgery",[23],{"name":24,"affiliation":5,"role":25},"Wenming Wu, doctor","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","+86 010-69156053",null,"doctorwuu@126.com",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":31},"+86 010-69156053 Wu, doctor",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":28,"phone":30,"phoneExt":30,"email":51},"Dingyan Cao, Dr.","caodingyan@pumch.cn",{"type":53,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100545891","phase-2-irinotecan-liposome-ii-in-combination-with-5-fulv-and-oxaliplatin-in-perioperative-treatment-of-borderline-resectable-pancreatic-cancer-100545891",false,"NCT06387810","Irinotecan Liposome II in Combination With 5-FU\u002FLV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer","Irinotecan Liposome II in Combination With 5-FU\u002FLV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer：A Prospective, Single-arm, Multicenter, Phase II Study","undetermined","Inclusion Criteria:\n\n* According to the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024.V1 edition), patients with critically resectable pancreatic cancer.\n* Have at least one measurable lesion as a target lesion (according to RECIST v1.1);\n* Have not received any anti-tumor therapy (including radiotherapy, ablation, chemotherapy, targeting, immunotherapy, etc.) or investigational drug therapy;\n* ECOG: 0 \\~ 1;\n* Expected survival ≥3 months;\n* Adequate organ and blood function\n\nExclusion Criteria:\n\n* Pancreatic cancer of non-pancreatic ductal origin includes patients with pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatic blastoma, and solid pseudopapillary tumor\n* Severe gastrointestinal dysfunction\n* Severe infection occurred within 4 weeks prior to initiation of treatment (CTCAE \\> Grade 2)\n* Blood clotting is abnormal, has a tendency to bleed, or is receiving thrombolytic or anticoagulant therapy\n* Have clinical symptoms or diseases of heart that are not well controlled, such as: (1) NYHA grade 2 or above heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction occurred within 6 months; (4) Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention\n* Known allergy to irinotecan liposome II, other liposome products, oxaliplatin, 5-FU, calcium leucovorin, and any component of the above products\n* Known peripheral neuropathy (CTCAE≥ Grade 3)\n* In the investigator's judgment, subjects had other factors that might have led to their being forced to terminate the study, such as non-adherence to the protocol, other serious medical conditions (including mental illness) requiring combined treatment, clinically significant abnormalities in laboratory test values, or family or social factors that might affect subjects' safety or the collection of trial data","ALL","18 Years","110 Years",{"count":66,"type":67},45,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU\u002FLV in perioperative treatment of borderline resectable pancreatic cancer in 45 patients.",[73],"Borderline Resectable Pancreatic Cancer",[75],"perioperative treatment, irinotecan liposome II","2024-07-08",{"date":78,"type":79},"2024-07-10","ACTUAL",{"date":81,"type":79},"2024-04-17",{"date":83,"type":67},"2026-06-30",{"name":5,"class":6},1]